+44 (0)1865 595230 nac.contact@lgcgroup.com
0 Items
Select Page

Our Norovirus Reagents

Noroviruses are a diverse group of seasonal RNA viruses that cause acute gastrointestinal infections in humans and animals. Due to the rate at with noroviruses undergo genetic shift, the immunity that they induce is typically short-lived and specific to the genotype in question. This has made the development of norovirus vaccines particularly challenging, as broad and long-lasting protection has proven difficult to achieve.

Due to the ongoing COVID-19 pandemic and implementation of lockdowns, human exposure to noroviruses has decreased sharply, leading to a decline in population immunity. As countries re-open, it is therefore likely that significant norovirus outbreaks will occur, requiring the development of various countermeasures.

To support norovirus R&D, The Native Antigen Company offers a range of norovirus-like particles and monoclonal antibodies, and is currently developing further reagents. For more information on these products, see our data below:

Norovirus-Like Particles

Our VLPs are non-infectious and safe to use, while displaying native-like epitopes and glycosylation patterns. A study by Metz and colleagues, for example, showed that our VirtuE™-expressed dengue VLPs exhibit comparable epitopes to native viral particles. Our VLPs are suitable for a wide range of applications, including the development of in vitro diagnostic assays and vaccines. The highly repetitive structural patterns presented by VLPs also makes them ideal antigens for raising high-avidity antibodies.

Norovirus Electron Micrograph
Norovirus SDS-PAGE

Negative staining electron micrograph of our norovirus-like particles (strain Hu/GI.1/CHA6A007/2010/USA).

Reducing SDS-PAGE of our norovirus-like particle VP1 proteins, migrating as a band of approximately 60kDa.

Norovirus Antibodies

Our mouse anti-norovirus GI and GII monoclonal antibodies are genogroup-specific and have shown not to react with adenovirus, astrovirus, Campylobacter jejuni, Clostridium difficile, Cryptosporidium parvum, enterovirus, Escherichia coli, Giardia lamblia, Helicobacter pylori, Hepatitis A, Listeria monocytogenes, rotavirus, respiratory syncytial virus, Salmonella, Shigella, Staphylococcus aureus and Yersinia enterocolitica.

Got any Questions?

Would you like to be kept informed of the latest news and innovations from the infectious disease community? Please let us know if you would like us to contact you or not by selecting one of the options below.

7 + 4 =

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...